WO2023058885A1 - 암 진단용 바이오마커 및 이의 용도 - Google Patents
암 진단용 바이오마커 및 이의 용도 Download PDFInfo
- Publication number
- WO2023058885A1 WO2023058885A1 PCT/KR2022/011996 KR2022011996W WO2023058885A1 WO 2023058885 A1 WO2023058885 A1 WO 2023058885A1 KR 2022011996 W KR2022011996 W KR 2022011996W WO 2023058885 A1 WO2023058885 A1 WO 2023058885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentration
- opn
- lpc
- hrg
- ratio
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 113
- 201000011510 cancer Diseases 0.000 title claims abstract description 108
- 239000000104 diagnostic biomarker Substances 0.000 title abstract 2
- 102000004264 Osteopontin Human genes 0.000 claims abstract description 543
- 108010081689 Osteopontin Proteins 0.000 claims abstract description 543
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims abstract description 450
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 claims abstract description 423
- 108010044853 histidine-rich proteins Proteins 0.000 claims abstract description 423
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 claims abstract description 369
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 119
- 201000007270 liver cancer Diseases 0.000 claims abstract description 118
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 116
- 201000005202 lung cancer Diseases 0.000 claims abstract description 116
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 116
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000003745 diagnosis Methods 0.000 claims abstract description 36
- 108010028776 Complement C7 Proteins 0.000 claims abstract description 23
- 102100024336 Complement component C7 Human genes 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 210000002966 serum Anatomy 0.000 claims abstract description 13
- 210000004369 blood Anatomy 0.000 claims description 173
- 239000008280 blood Substances 0.000 claims description 173
- 239000000090 biomarker Substances 0.000 claims description 70
- 238000002965 ELISA Methods 0.000 claims description 24
- 210000002381 plasma Anatomy 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 14
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 230000036765 blood level Effects 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 201000009036 biliary tract cancer Diseases 0.000 claims description 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 238000003795 desorption Methods 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 238000001269 time-of-flight mass spectrometry Methods 0.000 claims description 6
- 238000012744 immunostaining Methods 0.000 claims description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 5
- 239000013068 control sample Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 230000000951 immunodiffusion Effects 0.000 claims description 3
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 3
- 238000000670 ligand binding assay Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 abstract description 28
- 239000000463 material Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 154
- 239000003550 marker Substances 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 238000005406 washing Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 12
- 239000010421 standard material Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 238000008157 ELISA kit Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 8
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 8
- 238000002552 multiple reaction monitoring Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108091023037 Aptamer Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 206010073069 Hepatic cancer Diseases 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102000008928 Complement component C7 Human genes 0.000 description 2
- 108050000890 Complement component C7 Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010063628 acarboxyprothrombin Proteins 0.000 description 2
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 2
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
Definitions
- the present invention relates to a biomarker for cancer diagnosis and its use, and more particularly, to complement component 7 (C7) in blood, dodecanoyl-L-carnitine (Dodecanoyl-L-carnitine, DC), rhizophosphatidylcholine (A composition for diagnosing or predicting cancer including a substance measuring the levels of two or more markers selected from the group consisting of Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG), and Osteopontin, and cancer diagnosis or prognosis using the same It is about how to provide information about.
- LPC Lysophosphatidylcholine
- HRG Histidine-Rich Glycoprotein
- Osteopontin Osteopontin
- Cancer is a disease in which cells proliferate indefinitely and interfere with normal cell functions. Representative examples include liver cancer, lung cancer, stomach cancer, breast cancer, colon cancer, and ovarian cancer, but can occur in virtually any tissue.
- cancer diagnosis was based on external changes in biological tissue due to the growth of cancer cells, but in recent years, detection of trace amounts of biomolecules present in tissues or cells of organisms such as blood, glyco chain, and DNA has been used. Diagnosis is being attempted. However, the most commonly used cancer diagnosis method is diagnosis using a tissue sample obtained through biopsy or imaging.
- the biopsy causes great pain to the patient, is expensive, and takes a long time to diagnose.
- the patient actually has cancer there is a risk that cancer metastasis may be induced during the biopsy process, and in the case of areas where a tissue sample cannot be obtained through biopsy, a suspected tissue may be surgically performed.
- a disadvantage in that it is impossible to diagnose the disease before the extraction of the disease.
- liver cancer is diagnosed when AFP is increased to 20 ng/mL or more, but the diagnosis using AFP has a disadvantage in that the sensitivity is as low as 40%. That is, since AFP-negative liver cancer accounts for 40% or more of all liver cancers, an additional marker that can more accurately and effectively increase the liver cancer diagnosis rate is needed.
- AFP alpha-Fetoprotein
- DCP Descarboxyprothrombin
- PIVKA-II Prothrombin Induced by Vitamin K Absence II
- glycosylated AFP versus total AFP (L3 fraction) distribution AFU (alpha fucosidase)
- glypican 3 HSP-70.
- DCP Descarboxyprothrombin
- PIVKA-II Prothrombin Induced by Vitamin K Absence II
- glycosylated AFP versus total AFP (L3 fraction) distribution glycosylated AFP versus total AFP (L3 fraction) distribution
- AFU alpha fucosidase
- glypican 3 HSP-70
- lung cancer is one of the cancers with a high mortality rate worldwide, and currently, lung cancer is highly dependent on imaging methods (X-ray, CT, MRI, etc.).
- imaging methods X-ray, CT, MRI, etc.
- more than half of lung cancer patients are already inoperable at the time of discovery, and even if surgery is performed because it is judged that surgery is possible, complete resection is impossible in many of them. Therefore, in order to increase the cure rate of lung cancer, early diagnosis and treatment of lung cancer is most important, but detailed diagnosis of lung cancer is difficult because useful markers for diagnosis are limited. Therefore, there is a demand for the development of cancer-specific markers present in biological samples and methods for diagnosing cancer with high accuracy and precision using these markers.
- C7 complement component 7
- LPC Lysophosphatidylcholine
- HRG Histidine-Rich Glycoprotein
- OPN Osteopontin
- an object of the present invention is to treat complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), HRG (Complement Component 7, C7) in blood, plasma or serum.
- a composition for diagnosing cancer containing a substance for measuring the levels of two or more markers selected from the group consisting of Histidine-Rich Glycoprotein) and Osteopontin (OPN), a kit for diagnosing cancer using the same, and providing information for diagnosing cancer to provide a way
- Another object of the present invention is to treat complement component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), and histidine (HRG) in blood, plasma or serum.
- C7 complement component 7
- DC dodecanoyl-L-carnitine
- LPC lysophosphatidylcholine
- HRG histidine
- C7 complement component 7
- DC dodecanoyl-L-carnitine
- LPC lysophosphatidylcholine
- HRG histidine
- Osteopontin Osteopontin
- a composition for predicting cancer prognosis containing a substance measuring the level of two or more markers selected from the group consisting of, a kit for diagnosing cancer prognosis using the same, and information for predicting cancer prognosis It is to provide a way to provide.
- the present invention relates to Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin ( Includes two or more biomarkers selected from the group consisting of Osteopontin, OPN),
- the biomarker is extracted from blood,
- the blood may be whole blood, plasma or serum.
- the cancer may be lung cancer, pancreatic cancer, biliary tract cancer, colon cancer, breast cancer, stomach cancer, brain tumor, kidney cancer, liver cancer or cervical cancer.
- the lysophosphatidylcholine may be Lysophosphatidylcholine 16:0 (LPC16) or Lysophosphatidylcholine 18:0 (LPC18).
- cancer when the cancer is lung cancer,
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 180 to 210, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is lung cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 170 to 220, and if the ratio of the sum of the HRG concentration and the LPC concentration in the blood is less than the cutoff value, it is lung cancer,
- the cutoff value for the product of the C7 concentration and the OPN concentration is 8200 to 9000, and if the ratio of the product of the C7 concentration and the OPN concentration in the blood is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 95 to 270, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is greater than the cutoff value, it is lung cancer;
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG + LPC)) of (the product of the C7 concentration and the OPN concentration): (the sum of the DC concentration, the HRG concentration, and the LPC concentration) is between 40 and 40. 101, and if the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration, HRG concentration, and LPC concentration) in the blood is greater than the cutoff value, it can be regarded as lung cancer.
- the cancer when the cancer is liver cancer,
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 158 to 195, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is liver cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 140 to 175, and if the ratio of the sum of the HRG concentration and the LPC concentration in blood is less than the cutoff value, it is liver cancer,
- the cutoff value for the ratio of the product of the C7 concentration and the OPN concentration is 11700 to 17900, and if the ratio of the product of the C7 concentration and the OPN concentration in blood is greater than the cutoff value, it is liver cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is liver cancer.
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 150 to 265, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is above the cutoff value, it is liver cancer,
- the present invention provides a composition for diagnosing cancer comprising an agent for measuring the blood level of the biomarker composition for diagnosing cancer.
- the agent for measuring the level of the C7, HRG or OPN marker is an agent for measuring the protein level, an antibody that specifically binds to a protein or peptide fragment of each marker, an interaction It may include proteins, ligands, nanoparticles or aptamers.
- the preparation for measuring the level of the DC marker or LPC marker may be a preparation for mass spectrometry.
- the present invention provides a kit for diagnosing cancer comprising an agent for measuring the blood level of the biomarker composition for diagnosing cancer.
- the kit may be an enzyme linked immunosorbent assay (ELISA) kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit.
- ELISA enzyme linked immunosorbent assay
- MRM multiple reaction monitoring
- the present invention (a) Complement Component 7 (C7), dodecanoyl-L-carnitine (DC), lysophosphatidylcholine (LPC), HRG (Histidine) from the patient's blood Measuring the level of two or more biomarkers selected from the group consisting of -Rich Glycoprotein) and Osteopontin (OPN); and
- the cancer may be lung cancer, pancreatic cancer, biliary tract cancer, colon cancer, breast cancer, stomach cancer, brain tumor, kidney cancer, liver cancer, or cervical cancer.
- the blood in step (a) may be whole blood, plasma or serum.
- the lysophosphatidylcholine may be Lysophosphatidylcholine 16:0 (LPC16) or Lysophosphatidylcholine 18:0 (LPC18).
- cancer when the cancer is lung cancer,
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 180 to 210, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is lung cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 170 to 220, and if the ratio of the sum of the HRG concentration and the LPC concentration in the blood is less than the cutoff value, it is lung cancer,
- the cutoff value for the product of the C7 concentration and the OPN concentration is 8200 to 9000, and if the ratio of the product of the C7 concentration and the OPN concentration in the blood is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 95 to 270, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is greater than the cutoff value, it is lung cancer;
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG + LPC)) of (the product of the C7 concentration and the OPN concentration): (the sum of the DC concentration, the HRG concentration, and the LPC concentration) is between 40 and 40. 101, and if the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration, HRG concentration, and LPC concentration) in the blood is greater than or equal to the cut-off value, it can provide information that lung cancer is present.
- the cancer when the cancer is liver cancer,
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 158 to 195, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is liver cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 140 to 175, and if the ratio of the sum of the HRG concentration and the LPC concentration in blood is less than the cutoff value, it is liver cancer,
- the cutoff value for the ratio of the product of the C7 concentration and the OPN concentration is 11700 to 17900, and if the ratio of the product of the C7 concentration and the OPN concentration in blood is greater than the cutoff value, it is liver cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is liver cancer.
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 150 to 265, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is above the cutoff value, it is liver cancer,
- the level of C7, HRG or OPN biomarkers measured in step (a) is protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radiation immunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, Complement immobilization assay, two-dimensional electrophoretic analysis, liquid chromatography-Mass Spectrometry (LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blot and ELISA (enzyme linked immunosorbent assay).
- MALDI-TOF Microx Desorption/Ionization Time of Flight Mass Spectrometry
- SELDI-TOF Surface Enhanced Laser Desorption/I
- the measurement of the level of the DC or LPC biomarker in step (a) can be obtained by mass spectrometry of a sample in blood, plasma or serum with a mass peak area, specifically, It is obtained through liquid chromatography-mass spectrometry (LC-MS), and the mass spectrometer may be any one of Triple TOF, Triple Quadrupole, and MALDI TOF capable of quantitative measurement.
- mass spectrometry of a sample in blood, plasma or serum with a mass peak area
- LC-MS liquid chromatography-mass spectrometry
- the mass spectrometer may be any one of Triple TOF, Triple Quadrupole, and MALDI TOF capable of quantitative measurement.
- the present invention relates to Complement Component 7 (C7), Dodecanoyl-L-carnitine (DC), Lysophosphatidylcholine (LPC), Histidine-Rich Glycoprotein (HRG) and Osteopontin (A biomarker composition for predicting cancer prognosis is provided, comprising two or more biomarkers selected from the group consisting of osteopontin (OPN), wherein the biomarkers are extracted from blood.
- C7 Complement Component 7
- DC Dodecanoyl-L-carnitine
- LPC Lysophosphatidylcholine
- HRG Histidine-Rich Glycoprotein
- Osteopontin A biomarker composition for predicting cancer prognosis is provided, comprising two or more biomarkers selected from the group consisting of osteopontin (OPN), wherein the biomarkers are extracted from blood.
- OPN osteopontin
- the present invention provides a composition for predicting cancer prognosis comprising a substance for measuring the level of the biomarker for predicting cancer prognosis.
- the present invention provides a kit for diagnosing cancer prognosis including a substance for measuring the level of the biomarker for predicting cancer prognosis.
- the present invention provides a method for providing information for predicting cancer prognosis, comprising measuring the level of the biomarker for predicting cancer prognosis.
- complement component 7 C7
- DC dodecanoyl-L-carnitine
- LPC lysophosphatidylcholine
- HRG Histidine-Rich
- 1(A) is data confirming the concentration of C7 in blood obtained from a lung cancer patient group (LC) and a normal control group (Nor). Numerical values in the figure are shown as mean ⁇ standard error of the mean (SEM) value, and N means the number of patients. Also, Specificity means specificity, and Sensitivity means sensitivity.
- 1(B) is data confirming the concentration of DC in blood obtained from a lung cancer patient group and a normal control group.
- 1(C) is data confirming the concentration of HRG in blood obtained from a lung cancer patient group and a normal control group.
- Figure 1 (D) is data confirming the concentration of LPC in the blood obtained from lung cancer patient group and normal control group.
- 2(A) is data showing DC concentration, HRG concentration, and LPC concentration in blood obtained from a lung cancer patient group and a normal control group as the sum of the DC concentration, HRG concentration, and LPC concentration (DC + HRG + LPC).
- 2(B) is data showing the HRG concentration and LPC concentration in blood obtained from lung cancer patients and normal controls as the sum of the HRG concentration and LPC concentration (HRG + LPC).
- 2(C) is data showing the C7 concentration and OPN concentration in the blood obtained from lung cancer patients and normal controls as the product of the C7 concentration and the OPN concentration (C7 ⁇ OPN).
- 2(D) is data showing the C7 concentration, OPN concentration, and DC concentration in blood obtained from a lung cancer patient group and a normal control group as (C7 ⁇ OPN)/DC concentration ratio.
- 2(E) is data showing the C7 concentration, OPN concentration, and HRG concentration in blood obtained from a lung cancer patient group and a normal control group as (C7 ⁇ OPN)/HRG concentration ratio.
- 2(F) is data showing the concentration of C7, OPN, and LPC in blood obtained from lung cancer patients and normal controls as a (C7 ⁇ OPN)/LPC concentration ratio.
- 3(A) is data showing concentration ratio of C7, OPN, DC, and HRG in blood obtained from a lung cancer patient group and a normal control group as (C7 ⁇ OPN)/(DC + HRG) concentration ratio.
- 3(B) is data showing concentrations of C7, OPN, DC, and LPC in blood obtained from a lung cancer patient group and a normal control group as (C7 ⁇ OPN)/(DC + LPC) concentration ratio.
- FIG. 3(C) is data showing the C7 concentration, OPN concentration, HRG concentration, and LPC concentration in the blood obtained from lung cancer patients and normal controls as (C7 ⁇ OPN)/(HRG + LPC) concentration ratio.
- 3(D) is data showing the C7 concentration, OPN concentration, DC concentration, HRG concentration, and LPC concentration in the blood obtained from lung cancer patients and normal controls as (C7 ⁇ OPN)/(DC + HRG + LPC) concentration ratio.
- 4(A) is data confirming the concentration of C7 in blood obtained from a liver cancer patient group (HC) and a normal control group (Nor).
- 4(B) is data confirming the concentration of DC in blood obtained from a liver cancer patient group and a normal control group.
- 4(C) is data confirming the concentration of HRG in blood obtained from a liver cancer patient group and a normal control group.
- 4(D) is data confirming the concentration of OPN in blood obtained from a liver cancer patient group and a normal control group.
- 4(E) is data confirming the concentration of LPC in blood obtained from a liver cancer patient group and a normal control group.
- 5(A) is data showing DC concentration, HRG concentration, and LPC concentration in blood obtained from a liver cancer patient group and a normal control group as the sum of the DC concentration, HRG concentration, and LPC concentration (DC + HRG + LPC).
- 5(B) is data showing the HRG concentration and LPC concentration in blood obtained from a liver cancer patient group and a normal control group as the sum of the HRG concentration and LPC concentration (HRG + LPC).
- 5(C) is data showing the concentration of C7 and OPN in blood obtained from a liver cancer patient group and a normal control group as the product of the C7 concentration and the OPN concentration (C7 ⁇ OPN).
- 5(D) is data showing the concentration of C7, OPN, and DC in blood obtained from a liver cancer patient group and a normal control group as a (C7 ⁇ OPN)/DC concentration ratio.
- 5(E) is data showing the concentration of C7, OPN, and HRG in blood obtained from a liver cancer patient group and a normal control group in terms of (C7 ⁇ OPN)/HRG concentration ratio.
- 5(F) is data showing concentrations of C7, OPN, and LPC in blood obtained from a liver cancer patient group and a normal control group as a (C7 ⁇ OPN)/LPC concentration ratio.
- 6(A) is data showing concentrations of C7, OPN, DC, and HRG in blood obtained from a liver cancer patient group and a normal control group as (C7 ⁇ OPN)/(DC + HRG) concentration ratio.
- 6(B) is data showing concentrations of C7, OPN, DC, and LPC in blood obtained from a liver cancer patient group and a normal control group in terms of (C7 ⁇ OPN)/(DC + LPC) concentration ratio.
- 6(C) is data showing concentrations of C7, OPN, HRG, and LPC in blood obtained from liver cancer patients and normal controls as a (C7 ⁇ OPN)/(HRG + LPC) concentration ratio.
- 6(D) is data showing concentrations of C7, OPN, DC, HRG, and LPC in blood obtained from a liver cancer patient group and a normal control group as (C7 ⁇ OPN)/(DC + HRG + LPC) concentration ratio.
- complement C7 (Complement Component 7, C7)
- dodecanoyl-L-carnitine Dodecanoyl-L-carnitine, DC
- lysophosphatidylcholine LPC
- HRG Histidine-Rich Glycoprotein
- the biomarker is extracted from blood,
- the blood may be whole blood, plasma or serum.
- the cancer may be lung cancer, pancreatic cancer, biliary tract cancer, colon cancer, breast cancer, stomach cancer, brain tumor, kidney cancer, liver cancer, or cervical cancer, preferably liver cancer or lung cancer.
- the lysophosphatidylcholine may be Lysophosphatidylcholine 16:0 (LPC16) or Lysophosphatidylcholine 18:0 (Lysophosphatidylcholine 18:0, LPC18).
- the composition can diagnose cancer using one marker selected from the group consisting of C7, DC, LPC, HRG and OPN, preferably combining 2 to 5 markers, more preferably 'Combination of DC, HRG and LPC markers', 'Combination of HRG and LPC markers', 'Combination of C7 and OPN markers', 'Combination of C7, OPN and DC markers', 'Combination of C7, OPN and HRG markers' ', 'Combination of markers C7, OPN and LPC', 'Combination of markers C7, OPN, DC and HRG', 'Combination of markers C7, OPN, DC and LPC', 'Combination of markers C7, OPN, HRG and LPC' ', or 'a combination of C7, OPN, DC, HRG, and LPC markers' can be used to diagnose cancer.
- one marker selected from the group consisting of C7, DC, LPC, HRG and OPN, preferably
- the blood of a normal person, a lung cancer (LC) patient, and a liver cancer (HC) patient is obtained, respectively, and C7, DC, LPC, HRG, and OPN in the blood are obtained. Concentration was measured.
- FIGS. 1 (A) to 1 (D) lung cancer
- 4 (A) to 4 (E) liver cancer
- the cancer is lung cancer
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 180 to 210, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is lung cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 170 to 220, and if the ratio of the sum of the HRG concentration and the LPC concentration in the blood is less than the cutoff value, it is lung cancer,
- the cutoff value for the product of the C7 concentration and the OPN concentration is 8200 to 9000, and if the ratio of the product of the C7 concentration and the OPN concentration in the blood is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 95 to 270, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is greater than the cutoff value, it is lung cancer;
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG + LPC)) of (the product of the C7 concentration and the OPN concentration): (the sum of the DC concentration, the HRG concentration, and the LPC concentration) is between 40 and 40. 101, and if the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration, HRG concentration, and LPC concentration) in the blood is greater than the cutoff value, it can be regarded as lung cancer.
- the cancer is liver cancer
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 158 to 195, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is liver cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 140 to 175, and if the ratio of the sum of the HRG concentration and the LPC concentration in blood is less than the cutoff value, it is liver cancer,
- the cutoff value for the ratio of the product of the C7 concentration and the OPN concentration is 11700 to 17900, and if the ratio of the product of the C7 concentration and the OPN concentration in blood is greater than the cutoff value, it is liver cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is liver cancer.
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 150 to 265, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is above the cutoff value, it is liver cancer,
- the present invention relates to a composition for diagnosing cancer comprising an agent for measuring the blood level of the biomarker composition for diagnosing cancer of the present invention.
- composition for diagnosing cancer according to the present invention applies mutatis mutandis to the above-described ⁇ biomarker composition for diagnosing cancer>.
- the agent for measuring the level of the C7, HRG or OPN marker may be an agent for measuring the protein level
- the agent for measuring the level of the DC marker or LPC marker may be an agent for mass spectrometry.
- the agent for measuring the protein level may be an antibody, an interacting protein, a ligand, nanoparticles, or an aptamer that specifically binds to a protein or peptide fragment of a C7, HRG or OPN marker.
- an antibody refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction.
- an antibody refers to an antibody that specifically binds to a biomarker of the present invention.
- Antibodies of the present invention include both polyclonal antibodies, monoclonal antibodies and recombinant antibodies.
- aptamer is a biopolymer substance that inhibits protein interaction through three-dimensional binding with a specific target protein in the form of single or double helix DNA or RNA, and is a variety of target molecules. has the characteristic of binding to Typically, aptamers can be small nucleic acids, 15-50 bases in length, that fold into defined secondary and tertiary structures, such as stem-loop structures. The aptamer preferably binds to a target high- or low-expression protein with a kd of less than 10 ⁇ 6 , 10 ⁇ 8 , 10 ⁇ 10 , or 10 ⁇ 12 .
- the preparation for mass spectrometry refers to a preparation capable of analyzing the mass of a marker in blood, plasma or serum, and specifically, a preparation capable of performing liquid chromatography-mass spectrometry (LC-MS).
- LC-MS liquid chromatography-mass spectrometry
- the present invention relates to a kit for diagnosing cancer comprising an agent for measuring the blood level of the biomarker composition for diagnosing cancer of the present invention.
- composition for diagnosing cancer according to the present invention applies mutatis mutandis to the above-described ⁇ biomarker composition for diagnosing cancer>.
- the kit may be prepared by a conventional manufacturing method known in the art.
- the kit may include, for example, a freeze-dried antibody, a buffer, a stabilizer, and an inactive protein.
- the kit may further include a detectable label.
- detectable label means an atom or molecule that allows specific detection of a molecule containing a label among molecules of the same kind without a label.
- the detectable label may be attached to an antibody, interacting protein, ligand, nanoparticle, or aptamer that specifically binds to the protein or fragment thereof.
- the detectable label may include a radionuclide, a fluorophore, or an enzyme.
- the kit may be used according to various immunoassay methods or immunostaining methods known in the art.
- the immunoassay or immunostaining method may include radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, ELISA, capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry, immunofluorescence staining, and immunoaffinity purification.
- the kit may be an enzyme linked immunosorbent assay (ELISA) kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit.
- ELISA enzyme linked immunosorbent assay
- MRM multiple reaction monitoring
- complement C7 (Complement Component 7, C7), dodecanoyl-L-carnitine (Dodecanoyl-L-carnitine, DC), lysophosphatidylcholine (LPC) from patient's blood Measuring the level of two or more biomarkers selected from the group consisting of HRG (Histidine-Rich Glycoprotein) and Osteopontin (OPN); and
- the cancer may be lung cancer, pancreatic cancer, biliary tract cancer, colon cancer, breast cancer, stomach cancer, brain tumor, kidney cancer, liver cancer, or cervical cancer, preferably liver cancer or lung cancer.
- the lysophosphatidylcholine may be Lysophosphatidylcholine 16:0 (LPC16) or Lysophosphatidylcholine 18:0 (Lysophosphatidylcholine 18:0, LPC18).
- the method for providing information for diagnosing cancer when the cancer is lung cancer,
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 180 to 210, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is lung cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 170 to 220, and if the ratio of the sum of the HRG concentration and the LPC concentration in the blood is less than the cutoff value, it is lung cancer,
- the cutoff value for the product of the C7 concentration and the OPN concentration is 8200 to 9000, and if the ratio of the product of the C7 concentration and the OPN concentration in the blood is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is lung cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 95 to 270, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is greater than the cutoff value, it is lung cancer;
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG + LPC)) of (the product of the C7 concentration and the OPN concentration): (the sum of the DC concentration, the HRG concentration, and the LPC concentration) is between 40 and 40. 101, and if the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration, HRG concentration, and LPC concentration) in the blood is greater than or equal to the cut-off value, it can provide information that lung cancer is present.
- the cancer is liver cancer
- the cutoff value for the ratio of the sum of the DC concentration, HRG concentration and LPC concentration (DC + HRG + LPC) is 158 to 195, and if the ratio of the sum of the DC concentration, HRG concentration and LPC concentration in blood is less than the cutoff value It is liver cancer,
- the cutoff value for the ratio of the sum of the HRG concentration and the LPC concentration (HRG + LPC) is 140 to 175, and if the ratio of the sum of the HRG concentration and the LPC concentration in blood is less than the cutoff value, it is liver cancer,
- the cutoff value for the ratio of the product of the C7 concentration and the OPN concentration is 11700 to 17900, and if the ratio of the product of the C7 concentration and the OPN concentration in blood is greater than the cutoff value, it is liver cancer,
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + HRG)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is 55 to 140, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and HRG concentration) is greater than the cutoff value, it is liver cancer.
- the cutoff value for the ratio ((C7 ⁇ OPN)/(DC + LPC)) of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is 150 to 265, and If the ratio of (product of C7 concentration and OPN concentration): (sum of DC concentration and LPC concentration) is above the cutoff value, it is liver cancer,
- the level of C7, HRG or OPN biomarker in the blood in step (a) is measured by protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Desorption/Ionization Time of Flight Mass Spectrometry) ) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radiation immunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, 2 Dimensional electrophoretic analysis, liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blot and ELISA (enzyme linked immunosorbent assay) It can be done using
- the measurement of the level of DC or LPC biomarker in blood in step (a) can be obtained by mass spectrometry of a sample in blood, plasma or serum with a mass peak area, specifically, liquid chromatography- It can be obtained through mass spectrometry (LC-MS).
- the mass spectrometer may be any one of triple TOF, triple quadrupole, and MALDI TOF capable of quantitative measurement.
- the present invention provides complement C7 (Complement Component 7, C7), dodecanoyl-L-carnitine (Dodecanoyl-L-carnitine, DC), lysophosphatidylcholine (LPC), HRG (Histidine-Rich Glycoprotein) ) and at least two biomarkers selected from the group consisting of osteopontin (OPN), wherein the biomarkers are extracted from blood to provide a biomarker composition for predicting cancer prognosis.
- complement C7 Complement Component 7, C7
- dodecanoyl-L-carnitine Dodecanoyl-L-carnitine, DC
- LPC lysophosphatidylcholine
- HRG Histidine-Rich Glycoprotein
- OPN osteopontin
- the present invention relates to a composition for predicting cancer prognosis comprising an agent for measuring the blood level of the biomarker composition for predicting cancer prognosis.
- the present invention relates to a kit for diagnosing cancer prognosis comprising the composition for predicting cancer prognosis.
- composition or kit for predicting cancer prognosis according to the present invention apply mutatis mutandis to the above-described ⁇ composition for diagnosis of cancer> or ⁇ kit for diagnosis of cancer>.
- complement C7 (Complement Component 7, C7), dodecanoyl-L-carnitine (Dodecanoyl-L-carnitine, DC), lysophosphatidylcholine (LPC) from patient's blood Measuring the level of two or more biomarkers selected from the group consisting of HRG (Histidine-Rich Glycoprotein) and Osteopontin (OPN); and
- a step of providing information indicating that the cancer prognosis is poor may be additionally provided, and the above-described ⁇ Method of Providing Information on Cancer Diagnosis> applies mutatis mutandis.
- LC lung cancer
- C7 enzyme-linked immunosorbent assay was performed to measure the amount of C7 protein.
- the C7 ELISA kit used YN1203 ELISA Kit (INNOBATION BIO, Korea).
- the separated plasma was diluted 200,000 times using the diluted solution in the ELISA kit.
- standard materials for the preparation of the C7 standard curve were prepared according to the manufacturer's manual. The prepared samples and standards were placed in a C7 antibody-coated plate, sealed, and incubated at room temperature for 2 hours.
- Plasma was separated from the blood sample, and standard materials for each concentration necessary for a DC (Sigma, USA) standard curve were prepared. 400 ⁇ l of lipid extraction buffer (Abnova, Taiwan) was added to 20 ⁇ l of plasma and standards, followed by vortexing and centrifugation (10,000g, 5min, 4° C.). After centrifugation, the supernatant was transferred to a new tube and dried for 12 to 16 hours using a concentrator. Add 50 ⁇ l of 100% methanol containing 0.1% formic acid to the dried metabolite extract, dissolve well using a vortex, and analyze using LC-MS/MS (liquid chromatography - mass spectrometry/mass spectrometry) proceeded.
- LC-MS/MS liquid chromatography - mass spectrometry/mass spectrometry
- the LC used was a Shimadzu LC 40 system, and the MS was an AB Sciex Triple Quad 5500+ system.
- the MS was equipped with a Turbo Spray ion source.
- Analytical samples were separated in a BEH C18 column (1.7um, 2.1 ⁇ 50mm; Waters) of a Shimadzu LC 40 system.
- the solvent is a two-step linear gradient (solvent A, 0.1% FA in water; solvent B, 0.1% FA in 100% Acetonitrile; 5 to 55% solvent B 2.5 min, 55% solvent B 5.5 min, 55 to 95% solvent B 7.5 min, 95% solvent B 11 min, 95-5% solvent B 11.1 min and 5% solvent B 14.5 min) were used.
- Mass spectrometry was performed using multiple reaction monitoring (MRM) mode.
- MRM multiple reaction monitoring
- the area of the mass peak having the same mass value was calculated in the mass spectrum of the same time period as that of the metabolite corresponding to DC passing through the liquid chromatography.
- a standard curve was prepared using the mass peaks of the DC standard materials, and the mass peaks of each sample were substituted into the standard curve to measure the concentration of DC.
- Plasma was separated from the blood sample, and standard materials for each concentration required for an LPC (Avanti, USA) standard curve were prepared. 400 ⁇ l of lipid extraction buffer (Abnova, Taiwan) was added to 20 ⁇ l of plasma and standards, followed by vortexing and centrifugation (10,000g, 5min, 4° C.).
- the LC used was a Shimadzu LC 40 system, and the MS was an AB Sciex Triple Quad 5500+ system.
- the MS was equipped with a Turbo Spray ion source.
- Analytical samples were separated in a BEH C18 column (1.7um, 2.1 ⁇ 50mm; Waters) of a Shimadzu LC 40 system.
- the solvent is a two-step linear gradient (solvent A, 0.1% FA in water; solvent B, 0.1% FA in 100% Acetonitrile; 5 to 55% solvent B 2.5 min, 55% solvent B 5.5 min, 55 to 95% solvent B 7.5 min, 95% solvent B 11 min, 95-5% solvent B 11.1 min and 5% solvent B 14.5 min) were used.
- Mass spectrometry was performed using multiple reaction monitoring (MRM) mode.
- MRM multiple reaction monitoring
- the area of the mass peak having the same mass value was calculated in the mass spectrum of the same time period as that of the metabolite corresponding to LPC passing through the liquid chromatography.
- a standard curve was prepared using the mass peaks of the LPC standard materials, and the mass peaks of each sample were substituted into the standard curve to measure the concentration of LPC.
- HRG enzyme-linked immunosorbent assay was performed to measure the amount of HRG protein.
- HRG ELISA kit the HRG ELISA Kit (My BioSource, USA) was used.
- the separated plasma was diluted 100 times using the diluted solution in the ELISA kit.
- standard materials for HRG standard curve production were prepared according to the manufacturer's manual.
- the prepared samples and standards were placed in an HRG antibody-coated plate, sealed, and incubated at room temperature for 1 hour. After incubation for 1 hour, the contents of each plate well were removed and washed three times using a washing solution. After washing was completed, a detection antibody was added to the plate and incubated at room temperature for 1 hour. After 1 hour of incubation, the contents of each plate well were removed, and washing was repeated three times using a washing solution. After washing was completed, a substrate was added to the plate and incubated at room temperature for 30 minutes.
- osteopontin ELISA enzyme-linked immunosorbent assay
- the separated plasma was diluted 20-fold using the diluted solution in the ELISA kit. Before use, the ELISA kit was washed three times with a washing solution, and then standard materials for producing an osteopontin standard curve were prepared according to the manufacturer's manual. The prepared samples and standards were placed in an osteopontin antibody-coated plate, sealed, and incubated at room temperature at 60 rpm for 2 hours.
- FIGS. 1 (A) to 1 (D) it was confirmed that lung cancer patients showed a difference in the concentration of markers in blood from normal people. Specifically, the concentration of C7 was higher than that of normal people, DC, Concentrations of LPC or HRG were found to be low.
- a total of 117 patients were selected, and specifically, 100 normal and 17 hepatic cancer (HC) patients were selected and blood was collected. .
- HC hepatic cancer
- An enzyme-linked immunosorbent assay was performed in the same manner as in Example 1 to measure the amount of C7 protein.
- Liquid chromatography was performed in the same manner as in Example 1, and the area of the mass peak having the same mass value was calculated in the mass spectrum of the same time period as that of the metabolite corresponding to DC passing through the liquid chromatography.
- a standard curve was prepared using the mass peaks of the DC standard materials, and the mass peaks of each sample were substituted into the standard curve to measure the concentration of DC.
- Liquid chromatography was performed in the same manner as in Example 1, and the area of the mass peak having the same mass value was calculated in the mass spectrum of the same time period as that of the metabolite corresponding to LPC passing through the liquid chromatography.
- a standard curve was prepared using the mass peaks of the LPC standard materials, and the concentration of LPC was measured by substituting the mass peaks of each sample into the standard curve.
- An enzyme-linked immunosorbent assay was performed in the same manner as in Example 1 to measure the amount of HRG protein.
- An enzyme-linked immunosorbent assay was performed in the same manner as in Example 1 to measure the amount of osteopontin protein.
- liver cancer patients showed a difference in concentration of blood markers from normal people. Specifically, the concentrations of C7 and OPN were higher than those of normal people. , the concentration of DC, LPC or HRG was found to be low.
- complement component 7 C7
- DC dodecanoyl-L-carnitine
- LPC lysophosphatidylcholine
- HRG Histidine-Rich
- Osteopontin Osteopontin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (16)
- 보체 C7(Complement Component 7, C7), 도데카노일-L-카르니틴(Dodecanoyl-L-carnitine, DC), 리조포스파티딜콜린(Lysophosphatidylcholine, LPC), HRG(Histidine-Rich Glycoprotein) 및 오스테오폰틴(Osteopontin, OPN)으로 구성된 군에서 선택된 2종 이상의 바이오마커를 포함하며,상기 바이오마커는 혈액에서 추출한 것이고,상기 바이오마커가(1) DC, HRG 및 LPC인 경우, DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)로,(2) HRG 및 LPC인 경우, HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)로,(3) C7 및 OPN인 경우, C7 농도와 OPN 농도의 곱(C7 × OPN)으로,(4) C7, OPN 및 DC인 경우, (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)로,(5) C7, OPN 및 HRG인 경우, (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)로,(6) C7, OPN 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)로,(7) C7, OPN, DC 및 HRG인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))로,(8) C7, OPN, DC 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))로,(9) C7, OPN, HRG 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))로, 또는(10) C7, OPN, DC, HRG 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))로 암을 진단하는 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항에 있어서,상기 혈액은 전혈, 혈장 또는 혈청인 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항에 있어서,상기 암은 폐암, 췌장암, 담도암, 대장암, 유방암, 위암, 뇌종양, 신장암, 간암 또는 자궁경부암인 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항에 있어서,상기 리조포스파티딜콜린(LPC)은 리조포스파티딜콜린 16:0(Lysophosphatidylcholine 16:0, LPC16) 또는 리조포스파티딜콜린 18:0(Lysophosphatidylcholine 18:0, LPC18)인 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항에 있어서,상기 암이 폐암인 경우,(1) 상기 DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)에 대한 컷오프 값은 180 ~ 210 이며, 혈액 내 DC 농도, HRG농도 및 LPC 농도의 합의 비율이 컷오프 값 이하이면 폐암인 것으로,(2) 상기 HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)에 대한 컷오프 값은 170 ~ 220 이며, 혈액 내 HRG 농도와 LPC 농도의 합의 비율이 컷오프 값 이하이면 폐암인 것으로,(3) 상기 C7 농도와 OPN 농도의 곱(C7 × OPN)에 대한 컷오프 값은 8200 ~ 9000 이며, 혈액 내 C7 농도와 OPN 농도의 곱의 비율이 컷오프 값 이상이면 폐암인 것으로,(4) 상기 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)에 대한 컷오프 값은 340 ~ 812 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(5) 상기 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)에 대한 컷오프 값은 66 ~ 194 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(6) 상기 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)에 대한 컷오프 값은 155 ~ 370 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(7) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))에 대한 컷오프 값은 55 ~ 140 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로,(8) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))에 대한 컷오프 값은 95 ~ 270 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로,(9) 상기 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))에 대한 컷오프 값은 43 ~ 114 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로, 또는(10) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))에 대한 컷오프 값은 40 ~ 101 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로 보는 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항에 있어서,상기 암이 간암인 경우,(1) 상기 DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)에 대한 컷오프 값은 158 ~ 195 이며, 혈액 내 DC 농도, HRG농도 및 LPC 농도의 합의 비율이 컷오프 값 이하이면 간암인 것으로,(2) 상기 HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)에 대한 컷오프 값은 140 ~ 175 이며, 혈액 내 HRG 농도와 LPC 농도의 합의 비율이 컷오프 값 이하이면 간암인 것으로,(3) 상기 C7 농도와 OPN 농도의 곱의 비율(C7 × OPN)에 대한 컷오프 값은 11700 ~ 17900 이며, 혈액 내 C7 농도와 OPN 농도의 곱의 비율이 컷오프 값 이상이면 간암인 것으로,(4) 상기 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)에 대한 컷오프 값은 410 ~ 903 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(5) 상기(C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)에 대한 컷오프 값은 77 ~ 176 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(6) 상기 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)에 대한 컷오프 값은 207 ~ 359 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(7) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))에 대한 컷오프 값은 55 ~ 140 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로,(8) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))에 대한 컷오프 값은 150 ~ 265 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로,(9) 상기 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))에 대한 컷오프 값은 44 ~ 120 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로, 또는(10) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))에 대한 컷오프 값은 41 ~ 103 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로 보는 것을 특징으로 하는, 암 진단용 바이오마커 조성물.
- 제1항 내지 제6항 중 어느 한 항의 암 진단용 바이오마커 조성물의 혈액 내 수준을 측정하는 제제를 포함하는, 암 진단용 조성물.
- 제1항 내지 제6항 중 어느 한 항의 암 진단용 바이오마커 조성물의 혈액 내 수준을 측정하는 제제를 포함하는, 암 진단용 키트.
- (a) 환자의 혈액으로부터 보체 C7(Complement Component 7, C7), 도데카노일-L-카르니틴(Dodecanoyl-L-carnitine, DC), 리조포스파티딜콜린(Lysophosphatidylcholine, LPC), HRG(Histidine-Rich Glycoprotein) 및 오스테오폰틴(Osteopontin, OPN)으로 구성된 군에서 선택된 2종 이상의 바이오마커의 수준을 측정하는 단계; 및(b) 상기 바이오마커의 수준을 정상 대조군 시료와 비교하는 단계를 포함하며,상기 (a) 단계의 바이오마커가(1) DC, HRG 및 LPC인 경우, DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)로,(2) HRG 및 LPC인 경우, HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)로,(3) C7 및 OPN인 경우, C7 농도와 OPN 농도의 곱(C7 × OPN)으로,(4) C7, OPN 및 DC인 경우, (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)로,(5) C7, OPN 및 HRG인 경우, (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)로,(6) C7, OPN 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)로,(7) C7, OPN, DC 및 HRG인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))로,(8) C7, OPN, DC 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))로,(9) C7, OPN, HRG 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))로, 또는(10) C7, OPN, DC, HRG 및 LPC인 경우, (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))로 측정하는 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 (a) 단계의 혈액은 전혈, 혈장 또는 혈청인 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 암은 폐암, 췌장암, 담도암, 대장암, 유방암, 위암, 뇌종양, 신장암, 간암 또는 자궁경부암인 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 (a) 단계의 리조포스파티딜콜린(LPC)은 리조포스파티딜콜린 16:0(Lysophosphatidylcholine 16:0, LPC16) 또는 리조포스파티딜콜린 18:0(Lysophosphatidylcholine 18:0, LPC18)인 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 암이 폐암인 경우,(1) 상기 DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)에 대한 컷오프 값은 180 ~ 210 이며, 혈액 내 DC 농도, HRG농도 및 LPC 농도의 합의 비율이 컷오프 값 이하이면 폐암인 것으로,(2) 상기 HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)에 대한 컷오프 값은 170 ~ 220 이며, 혈액 내 HRG 농도와 LPC 농도의 합의 비율이 컷오프 값 이하이면 폐암인 것으로,(3) 상기 C7 농도와 OPN 농도의 곱(C7 × OPN)에 대한 컷오프 값은 8200 ~ 9000 이며, 혈액 내 C7 농도와 OPN 농도의 곱의 비율이 컷오프 값 이상이면 폐암인 것으로,(4) 상기 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)에 대한 컷오프 값은 340 ~ 812 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(5) 상기 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)에 대한 컷오프 값은 66 ~ 194 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(6) 상기 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)에 대한 컷오프 값은 155 ~ 370 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율이 컷오프 값 이상이면 폐암인 것으로,(7) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))에 대한 컷오프 값은 55 ~ 140 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로,(8) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))에 대한 컷오프 값은 95 ~ 270 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로,(9) 상기 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))에 대한 컷오프 값은 43 ~ 114 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로, 또는(10) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))에 대한 컷오프 값은 40 ~ 101 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 폐암인 것으로 정보를 제공하는 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 암이 간암인 경우,(1) 상기 DC 농도, HRG농도 및 LPC 농도의 합의 비율(DC + HRG + LPC)에 대한 컷오프 값은 158 ~ 195 이며, 혈액 내 DC 농도, HRG농도 및 LPC 농도의 합의 비율이 컷오프 값 이하이면 간암인 것으로,(2) 상기 HRG 농도와 LPC 농도의 합의 비율(HRG + LPC)에 대한 컷오프 값은 140 ~ 175 이며, 혈액 내 HRG 농도와 LPC 농도의 합의 비율이 컷오프 값 이하이면 간암인 것으로,(3) 상기 C7 농도와 OPN 농도의 곱의 비율(C7 × OPN)에 대한 컷오프 값은 11700 ~ 17900 이며, 혈액 내 C7 농도와 OPN 농도의 곱의 비율이 컷오프 값 이상이면 간암인 것으로,(4) 상기 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율((C7 × OPN)/DC)에 대한 컷오프 값은 410 ~ 903 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : DC 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(5) 상기(C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율((C7 × OPN)/ HRG)에 대한 컷오프 값은 77 ~ 176 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : HRG 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(6) 상기 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율((C7 × OPN)/LPC)에 대한 컷오프 값은 207 ~ 359 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : LPC 농도의 비율이 컷오프 값 이상이면 간암인 것으로,(7) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율((C7 × OPN)/(DC + HRG))에 대한 컷오프 값은 55 ~ 140 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 HRG 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로,(8) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + LPC))에 대한 컷오프 값은 150 ~ 265 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로,(9) 상기 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(HRG + LPC))에 대한 컷오프 값은 44 ~ 120 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로, 또는(10) 상기 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율((C7 × OPN)/(DC + HRG + LPC))에 대한 컷오프 값은 41 ~ 103 이며, 혈액 내 (C7 농도 및 OPN 농도의 곱) : (DC 농도 , HRG 농도 및 LPC 농도의 합)의 비율이 컷오프 값 이상이면 간암인 것으로 정보를 제공하는 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 (a) 단계에서 보체 C7, HRG 또는 OPN 바이오마커의 수준 측정은, 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Desorption/Ionization Time of Flight Mass Spectrometry)분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry)분석, 방사선 면역분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏 및 ELISA(enzyme linked immunosorbent assay)를 이용하여 수행하는 것을 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
- 제9항에 있어서,상기 (a) 단계에서 DC 바이오마커 또는 LPC 바이오마커의 수준 측정은, 액체크로마토그래피-질량분석기(LC-MS)를 통해 수득하는 것 특징으로 하는, 암 진단을 위한 정보를 제공하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280067888.3A CN118140143A (zh) | 2021-10-06 | 2022-08-11 | 用于诊断癌症的生物标志物及其用途 |
EP22878706.5A EP4414709A1 (en) | 2021-10-06 | 2022-08-11 | Diagnostic biomarker for cancer and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0132381 | 2021-10-06 | ||
KR20210132381 | 2021-10-06 | ||
KR1020220043778A KR102421471B1 (ko) | 2021-10-06 | 2022-04-08 | 암 진단용 바이오마커 및 이의 용도 |
KR10-2022-0043778 | 2022-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023058885A1 true WO2023058885A1 (ko) | 2023-04-13 |
Family
ID=82700896
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/011996 WO2023058885A1 (ko) | 2021-10-06 | 2022-08-11 | 암 진단용 바이오마커 및 이의 용도 |
PCT/KR2022/011990 WO2023058883A1 (ko) | 2021-10-06 | 2022-08-11 | 암 진단용 바이오마커 및 이의 용도 |
PCT/KR2022/011991 WO2023058884A1 (ko) | 2021-10-06 | 2022-08-11 | 암 진단용 바이오마커 및 이의 용도 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/011990 WO2023058883A1 (ko) | 2021-10-06 | 2022-08-11 | 암 진단용 바이오마커 및 이의 용도 |
PCT/KR2022/011991 WO2023058884A1 (ko) | 2021-10-06 | 2022-08-11 | 암 진단용 바이오마커 및 이의 용도 |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP4414709A1 (ko) |
KR (3) | KR102421466B1 (ko) |
CN (2) | CN118140143A (ko) |
WO (3) | WO2023058885A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102421466B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
KR20240054700A (ko) * | 2022-10-19 | 2024-04-26 | (주)이노베이션바이오 | 간암 진단용 바이오마커 및 간암 진단에 대한 인공지능 기반 정보 제공 방법 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120136583A1 (en) * | 2009-07-08 | 2012-05-31 | Worldwide Innovative Network | Method for predicting efficacy of drugs in a patient |
JP2013506142A (ja) * | 2009-10-01 | 2013-02-21 | フェノメノーム ディスカバリーズ インク | 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用 |
KR20140115490A (ko) | 2013-03-20 | 2014-10-01 | 서울대학교산학협력단 | 간암 진단용 바이오 마커 |
KR20160072027A (ko) | 2014-12-12 | 2016-06-22 | 서울대학교산학협력단 | 간암 진단용 바이오마커 및 그 용도 |
WO2019076830A1 (en) * | 2017-10-16 | 2019-04-25 | Biopredictive | METHOD OF PROGNOSIS AND MONITORING OF CANCER OF THE PRIMITIVE LIVER |
KR102156217B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 대장암 진단용 지질 바이오마커 및 이의 용도 |
KR20200116410A (ko) * | 2019-04-01 | 2020-10-12 | 국립암센터 | 고형암 진단 장치와 고형암 진단 정보 제공 방법 |
KR20210103212A (ko) * | 2020-02-13 | 2021-08-23 | (주) 프로탄바이오 | 폐암 진단용 다중 바이오마커 및 이의 용도 |
KR20210105270A (ko) * | 2020-02-18 | 2021-08-26 | (주)이노베이션바이오 | 동반진단용 바이오마커 조성물 및 이를 포함하는 동반진단용 키트 |
KR102421471B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9217749B2 (en) * | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
CA2803865A1 (en) * | 2010-06-23 | 2011-12-29 | University Of Louisville Research Foundation, Inc. | Methods for detecting cancer |
KR101334123B1 (ko) * | 2011-10-14 | 2013-11-28 | 서울대학교산학협력단 | 소세포폐암 진단용 조성물 및 소세포폐암 진단키트 |
KR20180012397A (ko) * | 2016-07-27 | 2018-02-06 | 주식회사 이스트컨트롤 | 디지털 음원 관리 시스템 및 방법, 디지털 음원 재생 장치 및 방법 |
KR102116178B1 (ko) * | 2017-05-10 | 2020-05-27 | 서울대학교산학협력단 | 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도 |
MX2020001575A (es) * | 2017-08-07 | 2020-11-18 | Univ Johns Hopkins | Materiales y métodos para evaluar y tratar el cáncer. |
-
2022
- 2022-04-08 KR KR1020220043775A patent/KR102421466B1/ko active IP Right Grant
- 2022-04-08 KR KR1020220043776A patent/KR102421469B1/ko active IP Right Grant
- 2022-04-08 KR KR1020220043778A patent/KR102421471B1/ko active IP Right Grant
- 2022-08-11 WO PCT/KR2022/011996 patent/WO2023058885A1/ko active Application Filing
- 2022-08-11 CN CN202280067888.3A patent/CN118140143A/zh active Pending
- 2022-08-11 WO PCT/KR2022/011990 patent/WO2023058883A1/ko active Application Filing
- 2022-08-11 EP EP22878706.5A patent/EP4414709A1/en active Pending
- 2022-08-11 EP EP22878704.0A patent/EP4414708A1/en active Pending
- 2022-08-11 WO PCT/KR2022/011991 patent/WO2023058884A1/ko unknown
- 2022-08-11 CN CN202280067887.9A patent/CN118140142A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120136583A1 (en) * | 2009-07-08 | 2012-05-31 | Worldwide Innovative Network | Method for predicting efficacy of drugs in a patient |
JP2013506142A (ja) * | 2009-10-01 | 2013-02-21 | フェノメノーム ディスカバリーズ インク | 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用 |
KR20140115490A (ko) | 2013-03-20 | 2014-10-01 | 서울대학교산학협력단 | 간암 진단용 바이오 마커 |
KR20160072027A (ko) | 2014-12-12 | 2016-06-22 | 서울대학교산학협력단 | 간암 진단용 바이오마커 및 그 용도 |
WO2019076830A1 (en) * | 2017-10-16 | 2019-04-25 | Biopredictive | METHOD OF PROGNOSIS AND MONITORING OF CANCER OF THE PRIMITIVE LIVER |
KR102156217B1 (ko) * | 2019-03-05 | 2020-09-15 | 연세대학교 산학협력단 | 대장암 진단용 지질 바이오마커 및 이의 용도 |
KR20200116410A (ko) * | 2019-04-01 | 2020-10-12 | 국립암센터 | 고형암 진단 장치와 고형암 진단 정보 제공 방법 |
KR20210103212A (ko) * | 2020-02-13 | 2021-08-23 | (주) 프로탄바이오 | 폐암 진단용 다중 바이오마커 및 이의 용도 |
KR20210105270A (ko) * | 2020-02-18 | 2021-08-26 | (주)이노베이션바이오 | 동반진단용 바이오마커 조성물 및 이를 포함하는 동반진단용 키트 |
KR102421471B1 (ko) * | 2021-10-06 | 2022-07-18 | (주)이노베이션바이오 | 암 진단용 바이오마커 및 이의 용도 |
Non-Patent Citations (1)
Title |
---|
STEFANIUK P ET AL., WORLD J GASTROENTEROL., vol. 16, 2010, pages 418 - 424 |
Also Published As
Publication number | Publication date |
---|---|
EP4414708A1 (en) | 2024-08-14 |
CN118140142A (zh) | 2024-06-04 |
KR102421469B1 (ko) | 2022-07-18 |
KR102421466B1 (ko) | 2022-07-18 |
KR102421471B1 (ko) | 2022-07-18 |
CN118140143A (zh) | 2024-06-04 |
WO2023058884A1 (ko) | 2023-04-13 |
WO2023058883A1 (ko) | 2023-04-13 |
EP4414709A1 (en) | 2024-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2023058885A1 (ko) | 암 진단용 바이오마커 및 이의 용도 | |
WO2021194188A1 (ko) | 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자 | |
WO2020080891A1 (ko) | 유방암 재발 예측 방법 | |
WO2017010852A1 (ko) | 염료 화합물 | |
WO2018038352A2 (ko) | 치매진단용 자가항체 바이오마커 및 이를 이용한 치매진단 방법 | |
WO2020032294A1 (ko) | 자성 나노입자를 이용한 바이오센서, 이를 이용하는 검출 장치 및 검출 방법 | |
WO2022114920A9 (ko) | 혈액 유래 엑소좀에서 발굴한 신규의 알츠하이머 진단용 바이오마커 및 이를 이용한 알츠하이머 진단방법 | |
WO2015126030A1 (ko) | 신규한 위암 진단방법 | |
WO2019182371A1 (ko) | 퇴행성 신경질환 진단용 조성물 | |
WO2019177345A1 (ko) | 초고감도 바이오마커 다중 검출 방법 | |
WO2011157222A1 (zh) | 淋巴瘤融合基因的联合检测方法及其诊断试剂盒 | |
WO2022211558A1 (ko) | 사스-코로나바이러스-2 스파이크 단백질의 에피토프에 결합하는 사스-코로나바이러스-2 중화 결합 분자 | |
CN101768639A (zh) | 一种甘蓝型油菜品种ssr指纹的快捷检测方法 | |
WO2018070652A1 (ko) | 당화혈색소 정량분석용 키트 | |
WO2012026743A2 (ko) | 라벨링제 및 이를 이용한 아미노산 서열 및 단백질 다중 정량 동시 분석방법 | |
WO2019235824A1 (ko) | Cox2 과발현 질환 진단용 조성물 및 이의 스크리닝 방법 | |
WO2020263063A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도 | |
WO2023177186A1 (ko) | 클릭반응을 이용한 cnt 필름, 이를 이용한 cnt 기반 바이오 센서 및 이의 제조방법 | |
WO2022158877A1 (ko) | 3차원 나노플라즈모닉 복합구조를 포함하는 기판, 이의 제조방법, 및 이를 이용한 신속 분석방법 | |
WO2022191566A1 (ko) | 췌장암의 진단용 조성물 | |
WO2018016916A1 (ko) | 레인 센서 | |
WO2022216111A1 (ko) | 암 진단용 조성물, 키트, 및 이를 이용한 암 진단 방법 | |
WO2024143624A1 (ko) | 체액 샘플 내의 분석 물질 농도를 측정하는 장치들, 시스템 및 방법 | |
WO2013100273A1 (ko) | 방사선 피폭 진단용 마커 igfbp-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법 | |
WO2021157818A1 (ko) | 그래핀 기반 신장 질환 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22878706 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18699078 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2024521214 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280067888.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022878706 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022878706 Country of ref document: EP Effective date: 20240506 |